Psoriasis: adalimumab found generally safe in meta-analysis

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review and meta-analysis suggest that adalimumab (Humira) is associated with a higher incidence of adverse events (AEs), but not serious AEs or discontinuation in patients with psoriasis.

Why this matters

  • Robust safety information can help guide treatment decisions.

Key results

  • Adalimumab was associated with higher incidence of AEs (15 trials; relative risk [RR], 1.05; 95% CI, 1.00-.109), infection (14 trials; RR, 1.10; 95% CI, 1.02-1.20), and injection site reaction (6 trials; RR, 1.80; 95% CI, 1.18-2.74) compared with control treatment.
  • Adalimumab and control treatment were associated with similar incidence of serious AEs (16 trials; RR, 1.06; 95% CI, 0.70-1.48), serious infection (9 trials; RR, 1.22; 95% CI, 0.61-2.44), and discontinuation caused by AE (13 trials; RR, 1.12; 95% CI, 0.80-1.57).
  • No significant publication bias was observed by Egger’s test (P=.299).

Study design

  • Patients with psoriasis, 3917 treated with adalimumab and 2583 control patients, from 20 RCTs were included in this meta-analysis of clinical safety.
  • Funding: None disclosed.

Limitations

  • Heterogeneity between included studies.